RxDoctor Payments Data

Zuleyma Toledo-Nieves

Neurology · Lakeland, FLNPI 1750838702

Payments from drug & device makers

$84,101in general payments, 2019–2025

Across 110 payments — averaging $764.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$78K
  • Genentech USA, Inc.$2K
  • Amgen$607
  • EMD Serono, Inc.$528
  • Sanofi$438
  • Bristol Myers Squibb$387
  • plus $2K from 19 others

What the payments were for

  • Consulting fees$1,7002%
  • Grants$78,00093%
  • Food & beverage$4,3275%
  • Education$740%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$84,101 in reported general payments places this provider in the 80th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$84,500
Medicare patients
251
Services billed
3,457

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab43$487,869
VumerityDiroximel Fumarate20$161,015
GilenyaFingolimod Hcl11$121,253
Nurtec OdtRimegepant Sulfate76$113,637
Aimovig AutoinjectorErenumab-Aooe108$80,410
BotoxOnabotulinumtoxina21$54,238
UbrelvyUbrogepant25$33,215
Emgality PenGalcanezumab-Gnlm34$23,378
BriviactBrivaracetam12$19,992
Dalfampridine ErDalfampridine25$8,808
Dimethyl Fumarate21$7,828
Rivastigmine17$3,935
Levetiracetam99$3,777
Memantine Hcl84$3,037
RivastigmineRivastigmine Tartrate46$2,806

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenVumerity$78,305$161,01520 claims
NovartisGilenya$181$121,25311 claims
PfizerNurtec Odt$241$113,63776 claims
AbbVieBotox, Ubrelvy$364$87,45346 claims
UCB, Inc.Briviact$93$19,99212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,434 neurology providers in Florida.

Other neurology in Lakeland

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →